STOCK TITAN

Genetic Technologies - GENE STOCK NEWS

Welcome to our dedicated page for Genetic Technologies news (Ticker: GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies stock.

Genetic Technologies Limited (GENE) delivers innovative genomic risk assessment solutions through its geneType and EasyDNA platforms. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in predictive diagnostics, strategic collaborations, and regulatory milestones.

Access official press releases covering quarterly earnings, product validations, patent approvals, and partnership announcements. Our curated feed simplifies tracking of GENE’s progress in integrating genetic insights into clinical decision-making and consumer health programs.

Discover updates about the company’s molecular testing innovations, including developments in oncology risk stratification and population health initiatives. Content spans financial disclosures, research breakthroughs, and global expansion efforts across healthcare markets.

Bookmark this page for streamlined access to verified information about Genetic Technologies’ operational developments. Check regularly for new insights into how GENE continues shaping personalized medicine through advanced DNA analysis technologies.

Rhea-AI Summary
Genetic Technologies (GTG) has recently announced transformative initiatives, including a partnership with Gold Coast Private Hospital for a 50-patient pilot study, a world-first risk assessment test for Melanoma, and a groundbreaking partnership with the University of Melbourne. These initiatives mark a significant leap forward in precision medicine and early disease detection, positioning geneType at the forefront of transforming DNA testing into a cost-effective, efficient tool for personalized cancer risk management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.45%
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited (GTG) announces a share consolidation of its ordinary shares and a change of ratio in its American Depositary Share program. The Effective Date is expected to be December 14, 2023. The Shares will continue to be traded on the ASX under the symbol “GTGDA”, from 14 December to 22 December 2023, before reverting to the symbol “GTG” from 27 December 2023. The ADSs will continue to be traded on The Nasdaq Stock Exchange under the symbol “GENE”.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE) provides an update on its activities for the quarter ending September 30, 2023. Highlights include a partnership with Gold Coast Private Hospital, geneType Multi-Test approval for Pancreatic Cancer, Melanoma, and Atrial Fibrillation in Australia, and being named the sole industry partner for a Medical Research Future Fund (MRFF) grant. Receipts from customers were A$2.0 million, and a peer-reviewed research paper validated geneType's Pancreatic Cancer risk test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
partnership clinical trial
Rhea-AI Summary
Genetic Technologies announces validation of Pancreatic Cancer risk assessment test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.29%
Tags
none
-
Rhea-AI Summary
RedChip Companies to air interviews with Knightscope, Soligenix, and Genetic Technologies on Bloomberg TV
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited announces partnership with Gold Coast Private Hospital to establish a Precision Medicine Clinic. Positive outcomes could lead to more clinics throughout Healthscope network.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
Rhea-AI Summary
RedChip Companies will air interviews with Aridis Pharmaceuticals, Genetic Technologies Limited, and American Resources Corporation on The RedChip Money Report®, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary
Genetic Technologies expands geneType Multi-Risk Test in Australia, offering assessments for Pancreatic Cancer, Melanoma, and Atrial Fibrillation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Genetic Technologies Limited receives grant for CASSOWARY Trial to assess multi-cancer genetic risk assessment in general practice. Results expected to change risk assessment and improve care. GTG to receive funding for test kits and analysis. Trial to recruit 600 participants from eight general practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (GENE) and 60 Degrees Pharmaceuticals (SXTP) on The RedChip Money Report, a sponsored program on Bloomberg TV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
Genetic Technologies

Nasdaq:GENE

GENE Rankings

GENE Stock Data

3.71M
4.85M
1.87%
0.53%
Diagnostics & Research
Healthcare
Link
Australia
Prahran